Bristol-Myers Squibb has been touted as a potential takeover target in the pharma industry – and potential buyers may take note of the continued strong performance of its cancer drug Opdivo
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
